4basebio PLC (ETR:88Q)

Market Cap	90.57M -47.9%
Revenue (ttm)	2.08M +198.5%
Net Income	-16.81M
EPS	-1.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	357
Open	5.65
Previous Close	5.65
Day's Range	5.65 - 5.65
52-Week Range	5.50 - 13.30
Beta	n/a
RSI	31.61
Earnings Date	May 22, 2026

About 4basebio

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccine...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 110
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 88Q

Financial Performance

In 2024, 4basebio's revenue was 933,000, an increase of 84.39% compared to the previous year's 506,000. Losses were -12.33 million, 60.9% more than in 2023.

Financial numbers in GBP